



Bristol-Myers Squibb Canada

“Bristol Myers Squibb established roots in Canada in 1925 and since that time, we have become a recognized player in the pharmaceutical industry with scientific breakthroughs that have advanced the treatment of serious diseases affecting Canadians. We have provided Canadian patients with much-needed treatment options for rheumatoid arthritis, stroke, venous thromboembolic events, psychotic conditions, diabetes, HIV, hepatitis C, metastatic melanoma, lung and renal cancer, among others.

At Bristol-Myers Squibb Canada, we are committed to making our medicines accessible to patients who need them. Through our collaboration with government and healthcare stakeholders, our goal is to build a stronger and more sustainable healthcare system that benefits all Canadians.

The work of our Canadian employees is bound together by one thing: the desire to help patients prevail over serious diseases. Patients are at the center of everything we do as we work towards delivering transformational medicines and make a meaningful difference.”

Join us on Tuesday, May 29, 2018, 07:00-08:15 for: **The Newest Oncologic Emergency: Management of Immune-related Adverse Events in Oncology Patients in The Era of Immune Checkpoint Inhibition**
Speaker: Dr. Jose Monzon, Moderator: Dr. Eddy Lang
Telus Exhibit Hall D

Learning Objectives

Upon completion of this program, participants will be able to:

- Differentiate challenging dermatological emergencies
- Describe the different clinical presentations
- Provide adjunctive pain and symptom management
- Recognize when and how to refer to a dermatologist

Introducing

Penthrox™

methoxyflurane



PENTHROX™ (methoxyflurane) is indicated for short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, in conscious adult patients.

Please consult the PENTHROX™ Product Monograph at <http://purdue.ca/en/products/Penthrox-PM> for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information which have not been

discussed in this piece. The Product Monograph is also available by calling Purdue Pharma at 1-800-387-4501.

Reference:

1. PENTHROX™ Product Monograph. Purdue Pharma. April 6, 2018.

PENTHROX™ is a trademark of Medical Developments International Limited, used under license by Purdue Pharma.
© 2018 Purdue Pharma. All rights reserved.



Purdue Pharma Inc
General Partner of / commandité de
Purdue Pharma
Pickering, Ontario L1W 3W8



Unexplained prolonged aPTT?¹ Suspect acquired hemophilia? Contact your hematologist



NiaStase RT® is indicated in adult patients with acquired hemophilia for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures.

Consult the product monograph at <http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/niaStase-product-monograph.pdf> for important information on contraindications, warnings, precautions, adverse reactions, interactions and dosing. The product monograph is also available by calling us at 1-800-465-4334.

Model used for illustrative purposes only.
aPTT=activated partial thromboplastin time

References: 1. Association of Hemophilia Clinic Directors of Canada. A guide to the management of patients with inhibitors to factor VIII and factor IX. 2010. 2. NiaStase RT® Product Monograph. November 10, 2017.

NiaStase RT® is a registered trademark of Novo Nordisk Health Care AG and is used under license by Novo Nordisk Canada Inc.

Novo Nordisk Canada Inc., Tel: (905) 629-4222 or 1-800-465-4334. www.novonordisk.ca



NiaStase RT®
Recombinant Factor VIIa



NEW 29G NEEDLE*

(20,000 anti Xa IU/mL
prefilled syringes only)



Pr **innohep**[®]
tinzaparin sodium

**The First & Only LMWH prefilled treatment syringes
with a 29 gauge (G) needle^{1,2†}**

innohep[®] (tinzaparin sodium) is indicated for:¹

- The treatment of deep vein thrombosis and/or pulmonary embolism.

For more information

Please consult the product monograph for innohep[®] at www.leo-pharma.ca/innohep_pm for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.

The product monograph is also available at www.leo-pharma.ca and by contacting Medical Information at LEO Pharma Inc., at 1-800-263-4218.

* clinical significance unknown

† comparative clinical significance unknown

References: 1. Current innohep[®] product monograph. LEO Pharma Inc.

2. Data on file, LEO Pharma Inc. Regulatory letter dated Dec 21, 2017.

© Registered trademark of LEO Pharma A/S used under license and distributed by LEO Pharma Inc., 123 Commerce Valley Dr. E., Suite 400. Thornhill, Ontario L3T 7W8

Pr **innohep**[®]
tinzaparin sodium





Introducing Your

MD Financial Suite

NEW. ENHANCED. EVOLVED.

New Ways to Invest With MD

For those who like to invest and trade on their own



MD Direct Trade™

Online trading platform provided by Canada's top-ranked online broker, Qtrade¹

+
Self
Managed

For those who want automated, low-cost digital advice plus access to a team of MD Advisors



MD ExO® Direct

Low-cost, digital investing and advice—made simple

+

For those who want to work with an MD Advisor



MD Plus™ account

Comprehensive advice across the full wealth management spectrum

+



MD Private Investment Counsel

Discretionary wealth management

+
Advisor
Managed

Questions? Contact Us

Call Client Services at 1 877 431-0330

Visit us at md.cma.ca/CAEP



MD Financial
Management
CMA Companies

¹ Qtrade Investor, Media Accolades, www.qtrade.ca/investor/about/media-accolades. • MD Direct Trade™ is a division of MD Management Limited, a member of the Canadian Investor Protection Fund. • MD ExO® Direct services are provided by MD Management Limited. Customers' accounts are protected by the Canadian Investor Protection Fund within specified limits. A brochure describing the nature and limits of coverage is available upon request. • MD Direct Trade™, MD ExO® and MD Plus™ are trademarks of the Canadian Medical Association (CMA), used under licence. • MD Private Investment Counsel offers investment counselling services, delivered by MD Financial Management Inc., a CMA company. • MD Financial Management provides financial products and services, the MD Family of Funds and investment counselling services through the MD Group of Companies.

LUCAS[®] 3 Chest Compression System

Proven. Smart. Built for the future.

Effective compressions, good blood flow lead to lifesaving CPR

High-quality CPR is key for good patient outcomes after sudden cardiac arrest, but is not always easy or possible to maintain manually. The LUCAS 3 device enables delivery of guidelines-consistent compressions from the moment it is turned on, helping to improve a patient's chance for a successful outcome.

Collects data on every compression

The LUCAS 3 device collects data on compressions, pauses, user interaction, alarms and battery information. For easy review of device and user action, data can be downloaded via Bluetooth[®], with no more cables to lose. The LUCAS 3 device is built on a data platform ready for the future of connectivity.


“It’s simple and easy to use, and it’s small and compact.”

*Dr. Charles Lick,
Medical Director, Allina Medical Transportation*

For more information please contact
physio-canada@stryker.com or call 1-800-668-8323.



CAEP | ACMU



1978-2018

CAEP CPD

OUR COURSES



AIME Advanced



Airway Interventions & Management in Emergencies



EDTUX
Diagnostics



EDTUX
Resuscitation



Emergency Department
Targeted Ultrasound



Emergency Medicine Review



Geriatric EM



Toxicology



CAEP members receive discounted registration fees

www.caep.ca

CAEP | ACMU



1978-2018

**BE ONE WITH
THE PAST,
PRESENT
AND FUTURE
OF
EMERGENCY
MEDICINE.**

It is always reassuring to know you are in good hands. Join CAEP today.

CAEP.CA/JOIN